Federal Trade Commission v. Golden Sunrise Nutraceutical, Inc., et al.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF CALIFORNIA 10 FEDERAL TRADE COMMISSION, No. 1:20-cv-01060-DJC-SKO 12 Plaintiff, 13 v. ORDER
GOLDEN SUNRISE NUTRACEUTICAL,
INC., et al., Defendants.
Plaintiff Federal Trade Commission (“FTC”) brought suit against Defendants in 2020, alleging that Defendants had advertised their products using false and unsubstantiated claims that Defendants’ products could treat, mitigate the symptoms of, or cure various ailments, including COVID-19, cancer, and Parkinson’s disease. Plaintiff also alleged that Defendants misrepresented that the Food and Drug Administration (“FDA”) had approved their products. Presently pending before the Court is Plaintiff’s long-pending Motion for Summary Judgment. (ECF No. 65.) For the reasons stated below, Plaintiff’s Motion for Summary Judgment is granted. BACKGROUND In July 2020, Plaintiff filed a complaint against Defendants Golden Sunrise Nutraceutical, Inc. (“GSN”), Golden Sunrise Pharmaceutical,…